Nuclera is a biotechnology company building eProtein Discovery, a desktop platform that integrates cell-free protein expression, digital microfluidics, and high-throughput screening to give researchers rapid access to purified proteins. The system reduces the time, cost, and uncertainty of protein production, allowing scientists to identify and validate candidates earlier in the drug-discovery process. With its latest focus on AI-enabled protein engineering, Nuclera is adding antibody-specific capabilities so users can perform end-to-end expression, purification, and binding validation of full-format antibodies on the same device. These new features are designed to generate large, standardized data sets suitable for training advanced machine-learning models in biologics R&D. Management positions the platform as a foundational tool for the fast-growing biologics segment, aiming to shorten therapeutic discovery timelines. The firm’s ongoing development is backed by considerable venture financing, now totaling $87 million in Series C capital.

Total raised

$132M

Funding rounds

5

Latest round

Series C

Latest activity

Jan 2026